- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Discusses Inclusion of Teplizumab in the ADA’s Living Standards of Care
Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA), outlines why updates were made to the ADA’s Living Standards of Care.
A number of important studies need to be recognized and reflected in updated diabetes guidelines, said Robert A. Gabbay, MD, PhD, the chief science and medical officer at the American Diabetes Association (ADA).
Transcript
Can you discuss the update for the Classification and Diagnosis of Diabetes, based on recent studies of teplizumab?
One of the things that we've been doing now for a few years is because diabetes, the field is moving so rapidly that we can't wait a whole year to be able to publish a new set of guidelines, because literally there are significant changes happening in between. That's why we've moved to this Living Standard model. The latest update from January until now was released because there were a number of important studies that needed to be recognized. One is around the role of teplizumab and the data from those studies that suggest delaying the onset of diabetes, on average 2 years, which, clinically, if you speak to any parent of a child with type 1 diabetes (T1D) or an individual with T1D, not having diabetes for 2 years matters. The guidelines reflect that new data and the opportunity to consider screening for T1D, for when the time comes when this drug will be available on the market, which we anticipate will be not too far away, based on recent FDA advisory group recommendations.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
What the Updated Telephone Consumer Protection Act Rules Mean for Health Care Messaging
April 4th 2025As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.
Read More
